---
title: "Top Altimmune Insider Makes Bold New Move on the Stock"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/270574190.md"
description: "Director Jerome Benedict Durso of Altimmune purchased 12,500 shares worth $51,500, signaling confidence in the company's future. Despite positive Phase 2b trial results for pemvidutide, Altimmune's stock dropped 21% to $3.98. Analysts remain neutral due to financial challenges and competitive landscape. Altimmune raised $54.6 million for development and aligned with the FDA for a Phase 3 trial. The stock's YTD performance is -45.15%, with a market cap of $406.9M."
datetime: "2025-12-23T02:04:33.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/270574190.md)
  - [en](https://longbridge.com/en/news/270574190.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/270574190.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/270574190.md) | [English](https://longbridge.com/en/news/270574190.md)


# Top Altimmune Insider Makes Bold New Move on the Stock

New insider activity at Altimmune ( (ALT) ) has taken place on December 22, 2025.

### Claim 70% Off TipRanks This Holiday Season

-   Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Director Jerome Benedict Durso has increased his stake in Altimmune by purchasing 12,500 shares of the company’s stock in a recent transaction, with the total value of the buy amounting to $51,500. This insider purchase may be seen by investors as a show of confidence in Altimmune’s future prospects.

**Recent Updates on ALT stock**

Over the last 24 hours, Altimmune’s share price has dropped about 21% to $3.98 despite the company reporting what it characterized as positive 48‑week topline Phase 2b MASH data for its lead candidate pemvidutide. The trial showed statistically significant improvements versus placebo in key non‑invasive fibrosis and liver‑health markers (such as ELF and liver stiffness), continued antifibrotic benefits from week 24 to week 48, additional weight loss at the higher dose without plateauing, and a favorable safety profile with fewer discontinuations than placebo. Altimmune also recently aligned with the FDA on the design of a registrational Phase 3 trial and is considering use of the FDA‑qualified AIM‑MASH AI pathology tool, while raising roughly $54.6 million via an at‑the‑market equity program to fund development. Recent analyst stance and price‑target adjustments referenced in the articles are driven by a balance between these encouraging clinical outcomes and regulatory progress on the one hand, and on the other hand the company’s ongoing profitability and cash‑flow challenges, the need for additional capital in a crowded and highly competitive MASH treatment landscape, and overall weak valuation metrics, leading analysts to frame the risk‑reward as more neutral despite the clinical momentum.

**Spark’s Take on ALT Stock**

According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.

Altimmune’s overall stock score is primarily impacted by its poor financial performance, with severe profitability and cash flow issues. The technical analysis indicates a bearish trend, and the valuation is unattractive due to negative earnings. Despite these challenges, the positive sentiment from the earnings call and corporate events provides some optimism for future growth.

To see Spark’s full report on ALT stock, click here.

**More about Altimmune**

**YTD Price Performance:** -45.15%

**Average Trading Volume:** 3,433,982

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $406.9M

### 相關股票

- [Altimmune (ALT.US)](https://longbridge.com/zh-HK/quote/ALT.US.md)

## 相關資訊與研究

- [Altimmune, Inc. (NASDAQ:ALT) Receives Consensus Rating of "Moderate Buy" from Brokerages](https://longbridge.com/zh-HK/news/281474009.md)
- [MedPal AI Wins Strong Shareholder Backing at AGM as It Expands AI Health Platform](https://longbridge.com/zh-HK/news/281501359.md)
- [LIC director Duncan Coull to step down at end of term](https://longbridge.com/zh-HK/news/280919645.md)
- [MedPal AI Updates Voting Rights as Share Count Reaches 492.4 Million](https://longbridge.com/zh-HK/news/281152846.md)
- [3 Best AI Stocks Set to Shine in April 2026, According to Analysts](https://longbridge.com/zh-HK/news/281421662.md)